SummaryThe clinical use of intravenous immunoglobulin (IVIg) has expanded beyond its traditional place in the treatment of patients with primary immunodeficiencies. Due to its multiple anti-inflammatory and immunomodulatory properties, IVIg is used successfully in a wide range of autoimmune and inflammatory conditions. Recognized autoimmune indications include idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome and other autoimmune neuropathies, myasthenia gravis, dermatomyositis and several rare diseases. Several other indications are currently under investigation and require additional studies to establish firmly the benefit of IVIg treatment. Increasing attention is being turned to the use of IVIg in combination with other agents, such as immunosuppressive agents or monoclonal antibodies. For example, recent studies suggest that combination therapy with IVIg and rituximab (an anti-CD20 monoclonal antibody) may be effective for treatment of autoimmune mucocutaneous blistering diseases (AMBDs), with sustained clinical remission. The combination of IVIg and rituximab has also been used in the setting of organ transplantation. Firstly, IVIg Ϯ rituximab has been administered to highly human leucocyte antigen (HLA)-sensitized patients to reduce anti-HLA antibody levels, thereby allowing transplantation in these patients. Secondly, IVIg in combination with rituximab is effective in the treatment of antibody-mediated rejection following transplantation. Treatment with polyclonal IVIg is a promising adjunctive therapy for severe sepsis and septic shock, but its use remains controversial and further study is needed before it can be recommended routinely. This review covers new developments in these fields and highlights the broad range of potential therapeutic areas in which IVIg may have a clinical impact.

3 patients with multiple sclerosis (MS) who developed severe widespread bullous pemphigoid (BP) are presented. MS preceded the presentation of BP by 13–23 years (mean 18 years). BP was confirmed histologically and immunopathologically. Upon successful therapy with steroids, no recurrence of BP was observed over a 3–5 year (mean 3.7 years) follow-up. Several abnormalities of the immune system have been reported in both diseases. It is interesting to speculate that amidst existing immunologic abnormalities in all 3 patients with MS, a specific event, immunologic or viral or both may have triggered the development of BP.

Among the oral agents, dapsone may be considered a first-line agent. This is primarily because the risk of potentially fatal adverse effects with this drug is lower than that associated with other available chemotherapeutic agents. In patients who are refractory to oral agents, alternative treatments have been used to prevent further disease progression. Recently, the use of IVIg therapy, with a defined protocol, has been reported to be beneficial. This therapy is promising since it may allow for discontinuation of all other therapies and is safe. The adverse effects from IVIg therapy are minimal. Furthermore, compared with other therapies, it provides a better quality of life.

HLA typing for A, B, and C locus antigens was performed on 70 patients with ocular cicatricial pemphigoid (OCP) and on 1849 controls. Additionally, typing for DR and DQ antigens and for the complement proteins (C2, factor B, C4A, and C4B) was performed on 63 patients and on the same control population. A significantly higher incidence of the following antigens was found in the OCP patients when compared to the control population: DR4 (43% in patients compared to 18% in controls, p = 0.0001); DR5 (41% compared to 16%, p = 0.0001); DQw3 (57% compared to 31%, p = 0.0010); A2 (60% compared to 28%, p = 0.0001); B8 (24% compared to 13%, p = 0.0086); B35 (19% compared to 9%, p = 0.0097); and B49 (7% compared to 2%, p = 0.0052). The complement types SC01, SC30, SC32, SC41, and SC42 were also significantly increased in patients compared to controls. No significant differences were found based on ethnic background, involvement of multiple mucous membranes, history of glaucoma, or deposition of specific immunoreactants in conjunctival biopsy samples. These findings may provide further insights into the pathogenesis of OCP and may help to localize a susceptibility gene for this autoimmune disease.

Although FK 506 was not used in a prospective randomized trial and although we used the drug only in patients with OCP refractory to conventional immunosuppressive agents, it is likely that FK 506 is incapable of controlling the activity of OCP and inducing a remission.

The results suggest that IL-5 may play an important role in the pathogenesis of OCP.

No abstract

Background: Alopecia areata is a disease scalp and body hair leading to patches of non-scoring alopecia which is heterogeyous ,it is unown as autommutte disease, there is no prevention & hard cure. Objective: To determine the prevalence  rate according to sex &age and the causative factors of alopecia areata in Baquba city. Patients and Methods: A cross-sectional study was in Baquba Teaching Hospital dermatological clinic from 1st of October 2020 to 31st of March 2022 at Baquabah teaching Hospital /outpatient Dermatology clinic. The study sample (100) patients with different clinical variants of Alopecia Areata, (71) males and (29) females of different age groups. Results: This study shows that high prevalence among males (71%) with age group (21-30) years old with single patchy alopecia areata with past history of recurrence and associated psychological history.  (100) cases of AA were diagnosed. (25%). Single lesion of AA was the most common manifestation (68%). Recurrence history of AA Positive in (55%). Personal history of stress was associated with AA in (64 %). The most common site of alopecia areata was in head (55%). Conclusion: It was concluded that, alopecia areata was more common in male, age (21-30) years, most common single lesion, more in head, with psychological stress history.